ACRS vs CGEM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ACRS · Aclaris Therapeutics$3.44 ▼ 1.71%
CGEM · Cullinan Therapeutics$8.89 ▼ 1.98%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ACRS +25.1%
- CGEM -31.2%
Head to head
| Metric | ACRS | CGEM |
|---|---|---|
| Price | $3.44 | $8.89 |
| Change today | ▼ 1.71% | ▼ 1.98% |
| Market cap | $545.63M | $577.15M |
| Return, 3 months | -45.5% | -59.3% |
| Return, year to date | +14.3% | -14.1% |
| Return, 1 year | +37.1% | -6.1% |
| P/E (TTM) | – | – |
| P/B | 3.3 | 2.1 |
| P/E percentile vs own 5y | 43rd | 53rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -55.1% | – |
| Net profit growth (YoY) | -26.7% | +2.4% |
| Gross margin | 5.8% | – |
| Operating margin | -1,412.4% | – |
| Net margin | -1,244.1% | – |
| Return on equity | -55.5% | -55.5% |
| Analyst target vs. price | +240.4% | +282.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 39 | 26 |
| 30-day volatility | 72.8% | 102.2% |
| Max drawdown, 1 year | -49.8% | -61.3% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CGEM is the largest of the group by market value.
- ACRS has returned the most over the past year.
- ACRS has been the calmest stock over the last 30 days.